Company Encyclopedia
View More
name
Bristol Myers Squibb
BMY.US
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis.
4.514 T
BMY.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking39/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE33.84%A
    • Profit Margin12.57%B
    • Gross Margin72.90%A
  • Growth ScoreC
    • Revenue YoY1.26%C
    • Net Profit YoY183.20%A
    • Total Assets YoY3.44%C
    • Net Assets YoY8.14%B
  • Cash ScoreC
    • Cash Flow Margin795.40%B
    • OCF YoY1.26%C
  • Operating ScoreC
    • Turnover0.5C
  • Debt ScoreE
    • Gearing Ratio80.80%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Bristol Myers Squibb Co. Stock Outperforms Competitors On Strong Trading Day

    Bristol Myers Squibb Co. (BMY) stock rose 1.94% to $51.95, outperforming competitors in a mixed market session. The S&P 500 increased by 0.11%, while the Dow Jones fell by 0.07%. This marks the second consecutive day of gains for BMY, which remains 17.97% below its 52-week high. Trading volume was 19.8 million, surpassing the 50-day average of 16.9 million.

    Dow Jones·
    US
    BMY
    +1.94%
    Dow Jones·
    US
    BMY
    +1.94%

    Top Pharmaceutical Stocks To Add to Your Watchlist - December 4th

    MarketBeat highlights Eli Lilly, Novo Nordisk, and Bristol Myers Squibb as top pharmaceutical stocks to watch. These companies offer exposure to healthcare innovation but carry risks related to clinical trials, regulatory approvals, and sector-specific activities. Despite Eli Lilly's moderate buy rating, analysts suggest other stocks may offer better returns.

    Market Beat·
    US
    BMY
    +1.94%
    US
    NVO
    +0.88%
    US
    LLY
    -1.85%
    Market Beat·
    US
    BMY
    +1.94%
    US
    NVO
    +0.88%
    US
    LLY
    -1.85%

    Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) | BMY Stock News

    Bristol Myers Squibb announced FDA approval of Breyanzi, a CAR T cell therapy, for adults with relapsed or refractory marginal zone lymphoma. Breyanzi is the first and only CAR T cell therapy approved for this condition, demonstrating high response rates and a consistent safety profile. This approval marks a significant advancement in treatment options for patients with this subtype of non-Hodgkin lymphoma.

    StockTitan·
    US
    BMY
    +1.94%
    StockTitan·
    US
    BMY
    +1.94%

    Trending | BMY Surges 5% on Wednesday, Some Call options Soar 460%

    On December 3, Eastern Time, Bristol Myers Squibb options saw a total of 124148 contracts traded, with calls accounting for 61% and puts making up 38%.

    LB Option·
    US
    BMY
    +1.94%
    LB Option·
    US
    BMY
    +1.94%

    Health Care Up on Alzheimer's Hopes - Health Care Roundup

    Health-care companies rose after one potential breakthrough on a brain disease. Bristol Myers Squibb rallied after the biopharmaceutical company said that it was adding patients for its study on its drug, Cobenfy, to treat psychosis in patients with Alzheimer's disease. Shares of Eisai, which produces Alzheimer's treatment Leqembi in collaboration with Biogen, fell slightly. Write to Rob Curran at rob.curran@dowjones.com (END) Dow Jones Newswires 12-03-25 1736ET

    marketscreener·
    US
    BMY
    +1.94%
    marketscreener·
    US
    BMY
    +1.94%
    Posts
    View More

    The Nasdaq Composite Index fell 2.7%, with a cumulative annual decline of 10.3%. - The S&P 500 Index dropped 1.97%, with a cumulative annual decline of 5.1%. - The Dow Jones Index declined 1.69%, with...

    © 2025 Longbridge｜Disclaimer